Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Amicus Therapeutics, Inc. (FOLD) since 2007 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Amicus Therapeutics, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1178879.
Total stock buying since 2007: $164,927,777.
Total stock sales since 2007: $289,464,081.
Total stock option exercises since 2007: $43,076,426.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 400 | $4,000 | 400 | $3,611 |
| 2024 | 0 | $0 | 399,658 | $5,124,634 | 182,067 | $1,360,541 |
| 2023 | 0 | $0 | 813,767 | $10,307,679 | 457,240 | $2,081,221 |
| 2022 | 0 | $0 | 424,370 | $4,449,738 | 116,155 | $466,726 |
| 2021 | 45,105 | $451,689 | 557,791 | $7,173,882 | 411,757 | $2,127,182 |
| 2020 | 11,000 | $175,512 | 1,681,390 | $24,511,559 | 1,284,060 | $8,873,723 |
| 2019 | 4,945 | $49,796 | 572,269 | $6,783,107 | 547,724 | $2,955,368 |
| 2018 | 1,235,827 | $15,744,014 | 301,765 | $4,590,161 | 201,765 | $1,644,814 |
| 2017 | 1,501,395 | $18,395,032 | 971,072 | $12,606,562 | 913,823 | $11,449,856 |
| 2016 | 592,950 | $3,020,945 | 1,260,420 | $8,649,277 | 156,358 | $50,864 |
| 2015 | 810,000 | $5,440,410 | 1,080,786 | $13,931,432 | 1,273,641 | $11,766,749 |
| 2014 | 6,467,084 | $30,224,665 | 11,682,909 | $62,446,695 | 16,491 | $10,521 |
| 2013 | 1,525,000 | $3,085,000 | 0 | $0 | 0 | $0 |
| 2012 | 9,361,554 | $55,128,673 | 0 | $0 | 49,931 | $31,955 |
| 2011 | 30,000 | $162,800 | 2,250 | $16,875 | 2,250 | $1,435 |
| 2010 | 11,898 | $43,903 | 0 | $0 | 0 | $0 |
| 2009 | 20,000 | $82,600 | 71,908 | $765,927 | 5,924 | $8,466 |
| 2008 | 1,834,162 | $27,685,294 | 677,689 | $127,429,143 | 153,582 | $191,652 |
| 2007 | 461,042 | $5,237,444 | 44,894 | $673,410 | 81,102 | $51,742 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2015-05-08 | Kirk John (VP, Regulatory Affairs) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Campbell Bradley L (Chief Operating Officer) | Option Ex | 50,000 | .00 | 0 |
| 2015-04-15 | Valenzano Ken (VP, Pharmacology & Biology) | Sale | 5,000 | 12.50 | 62,500 |
| 2015-04-15 | Valenzano Ken (VP, Pharmacology & Biology) | Option Ex | 5,000 | 12.50 | 62,500 |
| 2015-04-15 | Sblendorio Glenn (Director) | Sale | 20,000 | 12.50 | 250,000 |
| 2015-04-15 | Sblendorio Glenn (Director) | Option Ex | 20,000 | 12.50 | 250,000 |
| 2015-04-10 | Crowley John F (Chairman & CEO) | Sale | 11,678 | 12.00 | 140,136 |
| 2015-04-10 | Crowley John F (Chairman & CEO) | Option Ex | 11,678 | 12.00 | 140,136 |
| 2015-04-01 | Castelli Jeff (VP, Program Management) | Sale | 9,489 | 10.70 | 101,484 |
| 2015-04-01 | Castelli Jeff (VP, Program Management) | Option Ex | 9,489 | 10.70 | 101,484 |
| 2015-03-20 | Yu Julie (VP Clinical Ops & Data Mgmt) | Sale | 7,785 | 11.51 | 89,581 |
| 2015-03-20 | Yu Julie (VP Clinical Ops & Data Mgmt) | Option Ex | 7,785 | 11.51 | 89,581 |
| 2015-03-20 | Gershkowitz Jayne (VP, Patient Advocacy) | Sale | 10,648 | 11.51 | 122,569 |
| 2015-03-20 | Gershkowitz Jayne (VP, Patient Advocacy) | Option Ex | 10,648 | 11.51 | 122,569 |
| 2015-03-20 | Baird William D Iii (Chief Financial Officer) | Sale | 15,235 | 11.51 | 175,293 |
| 2015-03-20 | Baird William D Iii (Chief Financial Officer) | Option Ex | 15,235 | 11.51 | 175,293 |
| 2015-03-20 | Dilone Enrique (VP, Technical Operations) | Sale | 14,045 | 11.51 | 161,671 |
| 2015-03-20 | Dilone Enrique (VP, Technical Operations) | Option Ex | 14,045 | 11.51 | 161,671 |
| 2015-03-20 | Peist Kenneth (VP, Legal & IP) | Sale | 10,000 | 11.52 | 115,160 |
| 2015-03-20 | Peist Kenneth (VP, Legal & IP) | Option Ex | 10,000 | 11.52 | 115,160 |
| 2015-03-20 | Valenzano Ken (VP, Pharmacology & Biology) | Sale | 20,801 | 11.71 | 242,687 |
| 2015-03-20 | Valenzano Ken (VP, Pharmacology & Biology) | Option Ex | 19,093 | 11.60 | 221,063 |
| 2015-03-20 | Kirk John (VP, Regulatory Affairs) | Sale | 10,110 | 11.51 | 116,355 |
| 2015-03-20 | Kirk John (VP, Regulatory Affairs) | Option Ex | 10,110 | 11.51 | 116,355 |
| 2015-03-20 | Crowley John F (Chairman & CEO) | Sale | 268,322 | 11.49 | 3,082,214 |
| 2015-03-20 | Crowley John F (Chairman & CEO) | Option Ex | 268,322 | 11.49 | 3,082,214 |
| 2015-03-20 | Campbell Bradley L (Chief Operating Officer) | Sale | 12,999 | 11.51 | 149,592 |
| 2015-03-20 | Campbell Bradley L (Chief Operating Officer) | Option Ex | 12,999 | 11.51 | 149,592 |
| 2015-01-05 | Castelli Jeff (VP, Program Management) | Sale | 4,667 | 9.00 | 42,003 |
| 2015-01-05 | Castelli Jeff (VP, Program Management) | Option Ex | 4,667 | 9.00 | 42,003 |
| 2014-12-04 | Crowley John F (Chairman & CEO) | Buy | 89,000 | 8.36 | 743,951 |
| 2014-12-04 | Crowley John F (Chairman & CEO) | Sale | 89,000 | 8.36 | 743,951 |
| 2014-11-25 | Castelli Jeff (VP, Program Management) | Buy | 8,103 | 8.00 | 64,824 |
| 2014-11-25 | Castelli Jeff (VP, Program Management) | Sale | 8,103 | 8.00 | 64,824 |
| 2014-11-25 | Baird William D Iii (Chief Financial Officer) | Buy | 10,000 | 8.00 | 80,000 |
| 2014-11-25 | Baird William D Iii (Chief Financial Officer) | Sale | 10,000 | 8.00 | 80,000 |
| 2014-11-25 | Quimi Daphne (VP Finance and Controller) | Buy | 3,500 | 8.00 | 28,000 |
| 2014-11-25 | Quimi Daphne (VP Finance and Controller) | Sale | 3,500 | 8.00 | 28,000 |
| 2014-11-25 | Dilone Enrique (VP, Technical Operations) | Buy | 7,000 | 8.00 | 56,000 |
| 2014-11-25 | Dilone Enrique (VP, Technical Operations) | Sale | 7,000 | 8.00 | 56,000 |
| 2014-11-25 | Peist Kenneth (VP, Legal & IP) | Buy | 4,500 | 8.00 | 36,000 |
| 2014-11-25 | Peist Kenneth (VP, Legal & IP) | Sale | 4,500 | 8.00 | 36,000 |
| 2014-11-25 | Valenzano Ken (VP, Pharmacology & Biology) | Buy | 25,000 | 8.00 | 200,000 |
| 2014-11-25 | Valenzano Ken (VP, Pharmacology & Biology) | Sale | 25,000 | 8.00 | 200,000 |
| 2014-11-25 | Campbell Bradley L (Chief Operating Officer) | Buy | 7,250 | 8.00 | 58,000 |
| 2014-11-25 | Campbell Bradley L (Chief Operating Officer) | Sale | 7,250 | 8.00 | 58,000 |
| 2014-11-19 | Perceptive Life Sciences Master Fund Ltd | Buy | 2,100,000 | 6.50 | 13,650,000 |
| 2014-10-27 | Glaxosmithkline Plc | Sale | 11,315,825 | 5.29 | 59,872,030 |
| 2014-10-03 | Yu Julie (VP Clinical Ops & Data Mgmt) | Buy | 3,200 | 7.00 | 22,400 |
| 2014-10-03 | Yu Julie (VP Clinical Ops & Data Mgmt) | Sale | 3,200 | 7.00 | 22,400 |
| 2014-10-03 | Castelli Jeff (VP, Program Management) | Buy | 8,552 | 7.00 | 59,864 |
| 2014-10-03 | Castelli Jeff (VP, Program Management) | Sale | 8,552 | 7.00 | 59,864 |
| 2014-10-03 | Baird William D Iii (Chief Financial Officer) | Buy | 10,000 | 7.00 | 70,000 |
| 2014-10-03 | Baird William D Iii (Chief Financial Officer) | Sale | 10,000 | 7.00 | 70,000 |
| 2014-10-03 | Quimi Daphne (VP Finance and Controller) | Buy | 6,812 | 7.00 | 47,684 |
| 2014-10-03 | Quimi Daphne (VP Finance and Controller) | Sale | 6,812 | 7.00 | 47,684 |
| 2014-10-03 | Peist Kenneth (VP, Legal & IP) | Buy | 13,853 | 7.00 | 96,971 |
| 2014-10-03 | Peist Kenneth (VP, Legal & IP) | Sale | 13,853 | 7.00 | 96,971 |
| 2014-10-02 | Yu Julie (VP Clinical Ops & Data Mgmt) | Buy | 4,759 | 5.99 | 28,515 |
| 2014-10-02 | Yu Julie (VP Clinical Ops & Data Mgmt) | Sale | 4,759 | 5.99 | 28,515 |
| 2014-10-02 | Castelli Jeff (VP, Program Management) | Buy | 10,208 | 6.00 | 61,299 |
| 2014-10-02 | Castelli Jeff (VP, Program Management) | Sale | 10,208 | 6.00 | 61,299 |
| 2014-09-29 | Baird William D Iii (Chief Financial Officer) | Buy | 25,311 | 6.09 | 154,118 |
| 2014-09-29 | Baird William D Iii (Chief Financial Officer) | Sale | 25,311 | 6.09 | 154,118 |
| 2014-09-29 | Quimi Daphne (VP Finance and Controller) | Buy | 10,738 | 6.10 | 65,469 |
| 2014-09-29 | Quimi Daphne (VP Finance and Controller) | Sale | 10,738 | 6.10 | 65,469 |
| 2014-09-29 | Peist Kenneth (VP, Legal & IP) | Buy | 28,208 | 6.09 | 171,814 |
| 2014-09-29 | Peist Kenneth (VP, Legal & IP) | Sale | 28,208 | 6.09 | 171,814 |
| 2014-08-27 | Gershkowitz Jayne (VP, Patient Advocacy) | Buy | 5,000 | 7.00 | 35,000 |
| 2014-08-27 | Gershkowitz Jayne (VP, Patient Advocacy) | Sale | 5,000 | 7.00 | 35,000 |
| 2014-08-27 | Sblendorio Glenn (Director) | Buy | 10,000 | 6.50 | 65,000 |
| 2014-08-27 | Sblendorio Glenn (Director) | Sale | 10,000 | 6.50 | 65,000 |
| 2014-08-25 | Gershkowitz Jayne (VP, Patient Advocacy) | Buy | 5,000 | 6.00 | 30,000 |
| 2014-08-25 | Gershkowitz Jayne (VP, Patient Advocacy) | Sale | 5,000 | 6.00 | 30,000 |
| 2014-08-25 | Dilone Enrique (VP, Technical Operations) | Buy | 7,000 | 6.00 | 42,000 |
| 2014-08-25 | Dilone Enrique (VP, Technical Operations) | Sale | 7,000 | 6.00 | 42,000 |
| 2014-08-25 | Valenzano Ken (VP, Pharmacology & Biology) | Buy | 12,450 | 6.00 | 74,700 |
| 2014-08-25 | Valenzano Ken (VP, Pharmacology & Biology) | Sale | 12,450 | 6.00 | 74,700 |
| 2014-08-25 | Campbell Bradley L (Chief Operating Officer) | Buy | 7,000 | 6.00 | 42,000 |
| 2014-08-25 | Campbell Bradley L (Chief Operating Officer) | Sale | 7,000 | 6.00 | 42,000 |
| 2014-08-20 | Gershkowitz Jayne (VP, Patient Advocacy) | Buy | 6,080 | 5.40 | 32,832 |
| 2014-08-20 | Gershkowitz Jayne (VP, Patient Advocacy) | Sale | 6,080 | 5.40 | 32,832 |
| 2014-08-20 | Dilone Enrique (VP, Technical Operations) | Buy | 12,810 | 5.40 | 69,174 |
| 2014-08-20 | Dilone Enrique (VP, Technical Operations) | Sale | 12,810 | 5.40 | 69,174 |
| 2014-08-20 | Valenzano Ken (VP, Pharmacology & Biology) | Buy | 7,000 | 5.40 | 37,800 |
| 2014-08-20 | Valenzano Ken (VP, Pharmacology & Biology) | Sale | 7,000 | 5.40 | 37,800 |
| 2014-08-20 | Campbell Bradley L (Chief Operating Officer) | Buy | 18,750 | 5.40 | 101,250 |
| 2014-08-20 | Campbell Bradley L (Chief Operating Officer) | Sale | 18,750 | 5.40 | 101,250 |
| 2014-06-30 | Perceptive Life Sciences Master Fund Ltd | Buy | 4,000,000 | 3.50 | 14,000,000 |
| 2014-06-27 | Crowley John F (Chairman & CEO) | Option Ex | 16,491 | .64 | 10,521 |
| 2013-11-20 | Glaxosmithkline Plc | Buy | 1,500,000 | 2.00 | 3,000,000 |
| 2013-03-15 | Barer Sol J (Director) | Buy | 25,000 | 3.40 | 85,000 |
| 2012-11-13 | Winterbottom Joan (SVP, Human Resources) | Buy | 1,665 | 4.54 | 7,559 |
| 2012-07-17 | Glaxosmithkline Plc | Buy | 2,949,581 | 6.30 | 18,582,360 |
| 2012-03-30 | Crowley John F (Chairman & CEO) | Option Ex | 49,931 | .64 | 31,955 |
| 2012-03-07 | Sandell Scott D (10% Owner) | Buy | 925,154 | 5.70 | 5,273,377 |
| 2012-03-07 | Barrett M James (Director) | Buy | 925,154 | 5.70 | 5,273,377 |
| 2012-03-07 | Perry Mark W (10% Owner) | Buy | 1,140,000 | 5.70 | 6,498,000 |
| 2012-03-07 | Barris Peter J (10% Owner) | Buy | 1,140,000 | 5.70 | 6,498,000 |
| 2012-03-07 | Kramlich C Richard (10% Owner) | Buy | 1,140,000 | 5.70 | 6,498,000 |
| 2012-03-07 | Newhall Charles W Iii (10% Owner) | Buy | 1,140,000 | 5.70 | 6,498,000 |
| 2011-08-11 | Crowley John F (Chairman & CEO) | Buy | 10,000 | 4.20 | 42,000 |
| 2011-06-17 | Crowley John F (Executive Chairman) | Buy | 20,000 | 6.04 | 120,800 |
| 2011-05-24 | Valenzano Ken (VP, Pharmacology & Biology) | Sale | 2,250 | 7.50 | 16,875 |
| 2011-05-24 | Valenzano Ken (VP, Pharmacology & Biology) | Option Ex | 2,250 | .64 | 1,435 |
| 2010-03-02 | Crowley John F (Chairman, President & CEO) | Buy | 11,898 | 3.69 | 43,903 |
| 2009-11-04 | Barer Sol J (Director) | Buy | 20,000 | 4.13 | 82,600 |
| 2009-07-16 | Crowley John F (President & CEO) | Sale | 3,500 | 10.29 | 36,001 |
| 2009-07-15 | Crowley John F (President & CEO) | Sale | 6,500 | 10.69 | 69,472 |
| 2009-07-14 | Crowley John F (President & CEO) | Sale | 4,748 | 10.28 | 48,818 |
| 2009-07-13 | Crowley John F (President & CEO) | Sale | 800 | 10.09 | 8,068 |
| 2009-07-10 | Crowley John F (President & CEO) | Sale | 200 | 10.05 | 2,011 |
| 2009-07-09 | Crowley John F (President & CEO) | Sale | 1,652 | 10.24 | 16,918 |
| 2009-07-08 | Crowley John F (President & CEO) | Sale | 12,900 | 11.32 | 145,976 |
| 2009-07-07 | Crowley John F (President & CEO) | Sale | 6,200 | 11.42 | 70,785 |
| 2009-07-06 | Crowley John F (President & CEO) | Sale | 13,500 | 11.00 | 148,554 |
| 2009-06-29 | Palling David (Sr VP, Technical Operations) | Sale | 2,500 | 10.54 | 26,347 |
| 2009-06-26 | Palling David (Sr VP, Technical Operations) | Sale | 7,498 | 10.00 | 74,980 |
| 2009-03-30 | Palling David (Sr VP, Technical Operations) | Sale | 2 | 10.00 | 20 |
| 2009-03-25 | Palling David (Sr VP, Technical Operations) | Sale | 531 | 10.00 | 5,310 |
| 2009-03-23 | Palling David (Sr VP, Technical Operations) | Sale | 1,740 | 10.00 | 17,400 |
| 2009-03-19 | Palling David (Sr VP, Technical Operations) | Sale | 229 | 10.00 | 2,290 |
| 2009-03-11 | Crowley John F (President & CEO) | Option Ex | 1,000 | 5.33 | 5,325 |
| 2009-02-11 | Bloch Stephen M (Director) | Sale | 1,908 | 9.42 | 17,977 |
| 2009-02-03 | Palling David (Senior VP, Technical Operation) | Sale | 7,500 | 10.00 | 75,000 |
| 2009-01-08 | Palling David (Senior VP, Drug Development) | Option Ex | 4,924 | .64 | 3,141 |
| 2008-12-08 | Bloch Stephen M (Director) | Sale | 3,000 | 8.54 | 25,614 |
| 2008-12-03 | Bloch Stephen M (Director) | Sale | 25 | 8.50 | 212 |
| 2008-12-02 | Patterson Matthew R (Chief Operating Officer) | Option Ex | 20,098 | .64 | 12,822 |
| 2008-12-02 | Bloch Stephen M (Director) | Sale | 1,544 | 8.50 | 13,124 |
| 2008-12-01 | Bloch Stephen M (Director) | Sale | 4 | 8.90 | 35 |
| 2008-11-28 | Bloch Stephen M (Director) | Sale | 3,000 | 8.50 | 25,500 |
| 2008-11-26 | Bloch Stephen M (Director) | Sale | 3,000 | 8.52 | 25,551 |
| 2008-11-24 | Bloch Stephen M (Director) | Sale | 3,000 | 8.52 | 25,557 |
| 2008-11-21 | Bloch Stephen M (Director) | Sale | 2,436 | 8.50 | 20,706 |
| 2008-11-20 | Bloch Stephen M (Director) | Sale | 3,000 | 8.83 | 26,502 |
| 2008-11-19 | Bloch Stephen M (Director) | Sale | 3,000 | 9.03 | 27,096 |
| 2008-11-18 | Bloch Stephen M (Director) | Sale | 3,000 | 9.11 | 27,324 |
| 2008-11-17 | Bloch Stephen M (Director) | Sale | 7,740 | 9.02 | 69,830 |
| 2008-11-14 | Bloch Stephen M (Director) | Sale | 3,800 | 9.34 | 35,499 |
| 2008-11-13 | Bloch Stephen M (Director) | Sale | 3,000 | 9.41 | 28,218 |
| 2008-11-12 | Bloch Stephen M (Director) | Sale | 3,000 | 9.58 | 28,740 |
| 2008-11-11 | Bloch Stephen M (Director) | Sale | 3,000 | 9.20 | 27,597 |
| 2008-11-10 | Bloch Stephen M (Director) | Sale | 3,000 | 8.98 | 26,936 |
| 2008-11-07 | Bloch Stephen M (Director) | Sale | 3,000 | 9.08 | 27,240 |
| 2008-11-06 | Bloch Stephen M (Director) | Sale | 3,000 | 9.24 | 27,732 |
| 2008-11-05 | Bloch Stephen M (Director) | Sale | 3,900 | 10.04 | 39,163 |
| 2008-11-04 | Bloch Stephen M (Director) | Sale | 3,800 | 10.54 | 40,067 |
| 2008-11-03 | Crowley John F (President & CEO) | Sale | 10,000 | 10.28 | 102,780 |
| 2008-11-03 | Bloch Stephen M (Director) | Sale | 3,000 | 10.24 | 30,720 |
Insider trading activities including stock purchases, stock sales, and option exercises of FOLD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Amicus Therapeutics, Inc. (symbol FOLD, CIK number 1178879) see the Securities and Exchange Commission (SEC) website.